Unfortunately the goalposts are being moved in for
Post# of 148188
(Total Views: 780)
Posted On: 05/07/2020 2:53:29 PM
Re: penniestodimes #32675
Unfortunately the goalposts are being moved in for Gilead. Many doctors will not use remdesivir due to toxicity to the liver, lungs and kidneys beyond 5 days of treatment. Here's a comment from Seeking Alpha...
bjke
Comments7 | + Follow
"As a physician who has been working in the hospital in the ED, OR, ICU for over 20 years I can tell you that the science behind RANTES/CCL5 matches what we see clinically in the Covid 19 pts. There is NO other tx plan besides supportive care currently. I anticipate approval of leronlimab for emergency use based on their results. I would expect Big Pharma may put some roadblocks creating delays in approval and buy some time. Upside is huge for this co, even without the Covid 19 indication which just happened to pull the timeline closer and bigger.
BTW, lot of doctors are up in arms about how the G/R study was conducted with changes in endpoints midway to match the data and approval for a drug which has NO benefit on morbidity/mortality, has limited use due to severe toxicity to lungs liver and kidneys (already under attack from the dz, and the reason it is only a 5 day course as toxicity rises significantly after that) and has no role in critically I'll patients who have 88% mortality. No doubt big pharma pulling strings. If Gilead had leronlimab we would all be lining up at CVS to get it now, IMHO."
bjke
Comments7 | + Follow
"As a physician who has been working in the hospital in the ED, OR, ICU for over 20 years I can tell you that the science behind RANTES/CCL5 matches what we see clinically in the Covid 19 pts. There is NO other tx plan besides supportive care currently. I anticipate approval of leronlimab for emergency use based on their results. I would expect Big Pharma may put some roadblocks creating delays in approval and buy some time. Upside is huge for this co, even without the Covid 19 indication which just happened to pull the timeline closer and bigger.
BTW, lot of doctors are up in arms about how the G/R study was conducted with changes in endpoints midway to match the data and approval for a drug which has NO benefit on morbidity/mortality, has limited use due to severe toxicity to lungs liver and kidneys (already under attack from the dz, and the reason it is only a 5 day course as toxicity rises significantly after that) and has no role in critically I'll patients who have 88% mortality. No doubt big pharma pulling strings. If Gilead had leronlimab we would all be lining up at CVS to get it now, IMHO."
(12)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼